Predictions of biochemical recurrence following radical prostatectomy (RP) are currently ineffective. Now, researchers have developed an assay enabling the post-RP stratification of men with prostate cancer into three risk categories: low, intermediate, or high, based on proteomic analysis of RP specimens. Prognosis by assay score was found to be superior to all other preoperative parameters in predicting recurrence, and provided an additional improvement in risk stratification when combined with National Comprehensive Cancer Network staging score.